Your search for non small cell lung cancer returned 14 results

Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?

Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.

The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.

New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.

Starting treatment for advanced NSCLC before receiving genomic test results compromises patient outcomes, a study suggests.

Proton pump inhibitor use is associated with shorter survival among patients with non-small cell lung cancer treated with pembrolizumab monotherapy.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.

The approval was based on data from the CHECKMATE-816 trial.

The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.